• 不 限
  • 期刊论文
  • 硕博论文
  • 会议论文
  • 报 纸
  • 英文论文
  2. 您的位置
  3. 首页
  4. 会议论文
  5. Volasertib suppresses the growth of human hepatocellular carcinoma in vitro and in vivo

Volasertib suppresses the growth of human hepatocellular carcinoma in vitro and in vivo

来源 :2016医学科学前沿暨第四届个体化治疗与抗肿瘤药物研究新趋向研讨会 | 被引量 : 0次 | 上传用户：A312685521
【摘 要】
：
Hepatocellular carcinoma(HCC)is the sixth most frequent malignant tumor with poor prognosis,and its clinical therapeutic outcome is poor.Volasertib,a potent small molecular inhibitor of polo-like kina
【作 者】
：
Di-Wei Zheng You-Qiu Xue Jian-Ge Qiu Qi-Wei Jiang Xing Wei Zhi Shi 
【机 构】
：
Department of Cell Biology & Institute of Biomedicine,College of Life Science and Technology,Jinan U
【出 处】
：
2016医学科学前沿暨第四届个体化治疗与抗肿瘤药物研究新趋向研讨会
【发表日期】
：
2016年10期
下载到本地 , 更方便阅读
下载此文 赞助VIP
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
　　Hepatocellular carcinoma(HCC)is the sixth most frequent malignant tumor with poor prognosis,and its clinical therapeutic outcome is poor.Volasertib,a potent small molecular inhibitor of polo-like kinase 1(PLK1),is currently tested for treatment of multiple cancers in the clinical trials.
其他文献
Chelerythrine induces autophagy and inhibits the AKT/mTOR pathway in non-small cell lung cancer A549
Objective: Chelerythrine(CHE),a natural benzo[c]phenanthridine alkaloid presents in a number of plant species,has been known to exert various pharmacological effects.The autophagy inducing effects and
会议
chelerythrineautophagyapoptosisNSCLCmTOR
Treatment of osimertinib(AZD9291)-resistant non-small cell lung cancer HCC-827/OSIR cells by targeti
Objective: The third generation epidermal growth factor receptor(EGFR)tyrosine kinase inhibitor(TKI)osimertinib(OSI,also known as AZD9291)has been approved for treatment of EGFR T790M positive mutatio
会议
osimertinibAZD9291EGFRIRE1αNSCLC
Targeting tumor hypoxia of HCC by a novel drug candidate CT-707 through disruption of hypoxia-activa
Purpose: Intratumor hypoxia is a hallmark of hepatocellular carcinoma cells(HCC),leading to therapeutic resistance and malignant progression.Various strategies have been developed to combat with the h
会议
CT-707hepatocellular carcinomahypoxiaIGF-1RYAP
Marker-guided targeted therapy,PARP inhibitor,and novel post-translational modification of PD-L1
会议
Platycodin D markedly potentiates the anticancer activity of mTOR inhibitor everolimus in non-small
Objective: The mTOR inhibitors have been demonstrated clinical benefits in many cancers(kidney,breast cancer,etc),while the efficacy of mTOR inhibitors in non-small cell lung cancer(NSCLC)remains unce
会议
NSCLCeverolimusplatycodin DAKTcombinational therapy
Osthole inhibited epithelial-mesenchymal transition(EMT)by suppressing NF-κB mediated Snail activati
Objective: Osthole(OST),an active constituent of Chinese herb Cnidium monnieri,has been reported to inhibit cancer metastasis while the mechanisms remains unclear.Here,we studied the inhibitory effect
会议
EMTOstholeTGF-β1NF-κBSnail
Platycodin D inhibits Hsp90 activity by disrupting Hsp90/Cdc37 cochaperones interaction
Objective: Heat shock protein 90(Hsp90)is a therapeutic target for cancer treatment,and inhibition of Hsp90 will presumably result in suppression of multiple survival signaling pathways.Platycodin D(P
会议
Hsp90 inhibitorplatycodin DCdc37cochaperones interaction
2-Methoxy-6-Acetyl-7-Methyljuglone(MAM)Induces NO-Mediated DNA Damage Response
Objective: 2-Methoxy-6-acetyl-7-methyljuglone(MAM)is an active naphthoquinone component of Polygonum cuspidatum used as Chinese herb medicine for treatment of inflammation,hyperlipidemia and cancer.Th
会议
DNA damageMAMNitric oxideCancer
DS-36 protects against doxorubicin-induced cardiotoxicity by activating the JNK signaling pathway
Objective: Doxorubicin is a widely used antineoplastic agent in clinics for treating a wide range of cancers.However,the clinical use is largely limited by its cardiotoxicity of the heart.DS-36 is a n
会议
DS-36doxorubicincardiotoxicityROSJNK1/2
靶向G3BP的肿瘤治疗作用机制研究
会议